Citazo 2.25

Citazo 2.25 is a topical ophthalmic solution containing 2.25% citicoline (cytidine 5'-diphosphocholine), developed and marketed by Bioquest Pharmaceuticals. Citicoline is a naturally occurring endogenous intermediate in the biosynthesis of structural phospholipids, particularly phosphatidylcholine, which is a major component of neuronal cell membranes. In ophthalmology, Citazo 2.25 is utilized as a neuroprotective agent for the management of various ocular conditions, including glaucoma, optic neuropathy, and diabetic retinopathy. The drug is intended to support the structural integrity and repair of retinal ganglion cells and the optic nerve, which are often compromised in degenerative eye diseases. Additionally, citicoline may enhance visual function by modulating the levels of neurotransmitters such as dopamine and acetylcholine within the visual pathway.

Brand names

Citazo 2.25Citazo2.25Citazo-2.25Citazo

Other names

citicolineCDP-cholinecytidine 5'-diphosphocholineciticoline sodium